Intravitreal triamcinolone for diffuse diabetic macular oedema.

Hdl Handle:
http://hdl.handle.net/10147/208899
Title:
Intravitreal triamcinolone for diffuse diabetic macular oedema.
Authors:
Gibran, S K; Cullinane, A; Jungkim, S; Cleary, P E
Affiliation:
Department of Ophthalmology, Cork University Hospital, Cork, Ireland., syedgibran@yahoo.com
Citation:
Eye (Lond). 2006 Jun;20(6):720-4. Epub 2005 Jul 8.
Journal:
Eye (London, England)
Issue Date:
3-Feb-2012
URI:
http://hdl.handle.net/10147/208899
DOI:
10.1038/sj.eye.6701992
PubMed ID:
16021193
Abstract:
AIM: To evaluate the efficacy of intravitreal triamcinolone (IVTA) for the treatment of diffuse diabetic macular oedema (DME) refractory to conventional argon macular laser therapy. METHODS: A prospective, consecutive, and noncomparative case series was undertaken involving 38 eyes of 38 patients with refractory DME. Triamcinolone acetonide (4 mg) in 0.1 ml was injected intravitreally. LogMar visual acuity (VA) and macular thickness measured by ocular coherence tomography (OCT) were assessed preoperatively and postoperatively at 1, 3, and 6 months. RESULTS: All patients completed 6 months of follow up. VA (mean+/-SD) improved from 0.905+/-0.23 to 0.605+/-0.28, 0.555+/-0.29, and 0.730+/-0.30 at 1, 3, and 6 months, respectively. Macular thickness baseline (mean+/-SD) on OCT was 418.7+/-104.2 microm and this decreased to 276.9+/-72.6 microm, 250.6+/-53.1 microm, and 308.8+/-87.3 microm at 1, 3, and 6 months, respectively. CONCLUSIONS: IVTA may be a potential temporary treatment for refractory DME. It is effective in decreasing macular thickness and improving VA but the effect lasts approximately for 6 months in the majority of patients. Further investigations are required to establish the safety of IVTA for the treatment of DME.
Language:
eng
MeSH:
Aged; Anti-Inflammatory Agents/*therapeutic use; Diabetic Retinopathy/*drug therapy/pathology/physiopathology; Female; Humans; Macula Lutea/pathology; Macular Edema/*drug therapy/pathology/physiopathology; Male; Middle Aged; Prospective Studies; Treatment Outcome; Triamcinolone Acetonide/*therapeutic use; Visual Acuity/drug effects; Vitreous Body
ISSN:
0950-222X (Print); 0950-222X (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorGibran, S Ken_GB
dc.contributor.authorCullinane, Aen_GB
dc.contributor.authorJungkim, Sen_GB
dc.contributor.authorCleary, P Een_GB
dc.date.accessioned2012-02-03T15:06:51Z-
dc.date.available2012-02-03T15:06:51Z-
dc.date.issued2012-02-03T15:06:51Z-
dc.identifier.citationEye (Lond). 2006 Jun;20(6):720-4. Epub 2005 Jul 8.en_GB
dc.identifier.issn0950-222X (Print)en_GB
dc.identifier.issn0950-222X (Linking)en_GB
dc.identifier.pmid16021193en_GB
dc.identifier.doi10.1038/sj.eye.6701992en_GB
dc.identifier.urihttp://hdl.handle.net/10147/208899-
dc.description.abstractAIM: To evaluate the efficacy of intravitreal triamcinolone (IVTA) for the treatment of diffuse diabetic macular oedema (DME) refractory to conventional argon macular laser therapy. METHODS: A prospective, consecutive, and noncomparative case series was undertaken involving 38 eyes of 38 patients with refractory DME. Triamcinolone acetonide (4 mg) in 0.1 ml was injected intravitreally. LogMar visual acuity (VA) and macular thickness measured by ocular coherence tomography (OCT) were assessed preoperatively and postoperatively at 1, 3, and 6 months. RESULTS: All patients completed 6 months of follow up. VA (mean+/-SD) improved from 0.905+/-0.23 to 0.605+/-0.28, 0.555+/-0.29, and 0.730+/-0.30 at 1, 3, and 6 months, respectively. Macular thickness baseline (mean+/-SD) on OCT was 418.7+/-104.2 microm and this decreased to 276.9+/-72.6 microm, 250.6+/-53.1 microm, and 308.8+/-87.3 microm at 1, 3, and 6 months, respectively. CONCLUSIONS: IVTA may be a potential temporary treatment for refractory DME. It is effective in decreasing macular thickness and improving VA but the effect lasts approximately for 6 months in the majority of patients. Further investigations are required to establish the safety of IVTA for the treatment of DME.en_GB
dc.language.isoengen_GB
dc.subject.meshAgeden_GB
dc.subject.meshAnti-Inflammatory Agents/*therapeutic useen_GB
dc.subject.meshDiabetic Retinopathy/*drug therapy/pathology/physiopathologyen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHumansen_GB
dc.subject.meshMacula Lutea/pathologyen_GB
dc.subject.meshMacular Edema/*drug therapy/pathology/physiopathologyen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshProspective Studiesen_GB
dc.subject.meshTreatment Outcomeen_GB
dc.subject.meshTriamcinolone Acetonide/*therapeutic useen_GB
dc.subject.meshVisual Acuity/drug effectsen_GB
dc.subject.meshVitreous Bodyen_GB
dc.titleIntravitreal triamcinolone for diffuse diabetic macular oedema.en_GB
dc.contributor.departmentDepartment of Ophthalmology, Cork University Hospital, Cork, Ireland., syedgibran@yahoo.comen_GB
dc.identifier.journalEye (London, England)en_GB
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.